Navigation Links
Visual prostheses: Symposium to explore combining functional endpoints
Date:3/1/2011

Bethesda, MD The National Eye Institute (NEI) and Food and Drug Administration (FDA) are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acuity, visual fields and contrast sensitivity. These assessments may provide valuable information that will corroborate standard clinical test outcomes.

Today, functional vision outcomes such as how patients perform orientation and mobility tasks and other daily living activities are being incorporated more frequently into randomized clinical trials.

A growing body of evidence strongly suggests that functional vision data may provide a better understanding of what patients can actually do beyond the data obtained from visual acuity or visual field measurements. The FDA is already incorporating this type of clinical data into guidance for clinical trials of investigational visual prostheses.

Agenda highlights

  • Differentiate between functional vision and visual function
  • Provide an overview of guidance documents relevant to visual prostheses
  • Identify critical elements in orientation and mobility assessments as they relate to retinal implants
  • Identify critical elements of activities in daily living assessment necessary to establish effectiveness of retinal implants to improve visual function
  • Interactive/open discussion with leaders in the field of vision rehabilitation and visual prostheses regarding next steps

This meeting, part of an NEI/FDA series of Endpoints Symposia, will explore the issues and challenges related to functional vision information in ophthalmology. Participants will also look at FDA guidelines for using functional vision outcomes and how they are incorporated for the investigation and labeling of medical devices and drugs.

Faculty will include authorities in vision rehabilitation, orientation and mobility, occupational therapy, ophthalmology and optometry. FDA representatives will present insights about how the FDA reviews and evaluates functional vision outcomes in support of product labeling for visual prostheses and drugs used for the treatment of retinal diseases.

The goal of this meeting is to obtain recommendations for measuring specific tasks of mobility and daily living activities as well as how they will be analyzed and correlated with objective measures of visual acuity and contrast sensitivity in the clinical trial.

Who should attend?

  • clinical researchers/basic scientists in the visual prostheses field
  • retina specialists
  • clinical trialists
  • pharmaceutical company representatives
  • device company representatives
  • other biotechnology companies in the field of retinal stem cell implants
  • Low vision/vision rehabilitation researchers
  • Daily living activities researchers


'/>"/>

Contact: Katrina Norfleet
knorfleet@arvo.org
240-221-2924
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Related medicine news :

1. Eye expo at UH offers resources to the visually impaired
2. JPEG for the mind: How the brain compresses visual information
3. Kids With Autism May Lack Key Visual Skills, Study Finds
4. U of M researchers find learning in the visual brain
5. Visual pattern preference may be indicator of autism in toddlers
6. CWRU study finds visually impaired people get insulin pen dosages right
7. Apptera Raises $10M to Grow Its Voice And Visual Mobile Ad Network
8. Researchers predict human visual attention using computer intelligence for the first time
9. Visually guided laser may be viable treatment for abnormal heartbeat
10. Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15
11. Provalis Research Announces the Release of WordStat 6, Delivering Enhanced Analytical and Visualization Tools for Textual Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... University is taught by healthcare management and evaluation leaders with decades of experience ... to pay-for-value in the United States healthcare system, there is a renewed demand ...
(Date:1/23/2017)... ... 23, 2017 , ... The American Academy of Thermology ... development, healthcare training and clinical application of medical infrared imaging, has announced the ... Qualification Courses for Technicians, respectively. , For the first time the AAT is ...
(Date:1/23/2017)... ... 2017 , ... METTLER TOLEDO has announced the availability of ... PAT Tools . , Crystallization is a common step used during ... Chemists now spend more time developing better intermediate and final crystallization steps. ...
(Date:1/23/2017)... ... January 23, 2017 , ... Steviva Ingredients, makers of all-natural ... USDA National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... and handling systems to complement our current rigorous food-safety management systems,” said Yishu ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... ALBANY, New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn ... by expanding at a strong 17.50% CAGR between 2014 and 2022. ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... ...
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
Breaking Medicine Technology: